NAMD sent a letter to sponsors of the legislation, “Advancing Care for Exceptional for Kids.” The letter addresses the bill’s underlying structure and implementation issues as well as other opportunities to enhance access to care coordination and high quality services for children with complex medical needs. Read full letter.
NAMD sent a letter to House of Representatives leadership on the need to address the privacy laws governing substance use disorder information as part of opioid legislation under consideration in the House. The letter underscores the need to amend the privacy laws of 42 CFR Part 2 to fully address the opioid crisis, and ensure […]
On April 29, NAMD sent a letter to leadership of the Senate Finance Committee and the Senate Health, Education, Labor, and Pensions Committee addressing Senators’ efforts to improve the nation’s behavioral health system. In particular, NAMD praised the Committees for their consideration of lifting restrictions on federal Medicaid payments for services provided in Institutions for […]
NAMD submitted comments to the Substance Abuse and Mental Health Services Administration (SAMHSA) on a proposed rule addressing the confidentiality of substance use disorder information (42 CFR Part 2). In the letter, NAMD requests SAMHSA revise the proposed rule to better support care coordination and information exchange to ensure patient safety and positive outcomes. Read […]
NAMD submitted comments to CMS on the final Medicaid covered outpatient drug rule. In the comments, NAMD calls attention to implementation timeline challenges posed by the rule and provides a suggested approach for handling line extension drugs. Read full letter.
NAMD sent a letter to U.S. Department of Health and Human Services Secretary Sylvia Mathews Burwell to share the findings of a new value-based purchasing (VBP) report. Based on the report’s findings, the letter requests HHS support Medicaid value-based purchasing in three ways: by promoting Medicaid involvement in federal VBP initiatives, including the prospective payment […]
NAMD responded to a series of questions from the Senate Finance Committee on how to account for value in the pricing and coverage of breakthrough prescription drug therapies. The letter outlines potential policy options for improving the Medicaid Drug Rebate Program and other options to grant states additional tools for managing the impact of these […]
NAMD submitted a response to the December 2015 policy options paper issued by the Chronic Care Working Group of the Senate Committee on Finance. NAMD conveyed its strong support for permanent authorization for the Medicare Advantage Dual Eligible Special Needs Plan (D-SNP) program and called for reform of enrollment policies for the Medicare-Medicaid dual eligible […]
NAMD provided responses to a set of Senate Finance Committee questions regarding streamlining and improving Medicaid data reporting, as well as exploring avenues to enhance Medicaid’s access to other data sources. In the response, NAMD calls for reducing certain outdated reporting requirements, facilitating the sharing of Medicaid data between federal entities, and making other federal […]